Novel CAR T-cell vein-to-vein process could reduce time and cost
Drug Discovery World
FEBRUARY 1, 2024
A paper in BioRxiv has described a new process that could improve the chimeric antigen receptor (CAR) T-cell patient experience and reduce costs through a minimisation of the CAR T-cell therapy vein-to-vein process. The process utilises less than 300ml of whole blood from a blood draw instead of apheresis for the collection of T cells from patients undergoing chimeric antigen receptor CAR T-cell therapy.
Let's personalize your content